Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Recurrent Peritonitis in Peritoneal Dialysis Patients?

July 1, 2022

Abstract

The use of peritoneal dialysis in end-stage renal disease is increasing in clinical practice. The main purpose of this study was to evaluate the effect of far-infrared radiation therapy on inflammation and the cellular immunity of patients undergoing peritoneal dialysis. We recruited 56 patients undergoing peritoneal dialysis, and we included 32 patients for the experimental group and 24 patients from the control group in the final analysis. The experimental evaluation in our study was as follows: (1) We used abdominal computed tomography to explore the changes in abdominal blood vessels. (2)We compared the effects of peritoneal dialysis using blood glucose, HbAlC, albumin, urea nitrogen, creatinine, white blood cells, hs-CRP; peritoneal Kt/V of peritoneal function, and eGFR. (3) We compared the cytokines’ concentrations in the two groups while controlling for the other cytokines. Results and Discussion: (1) There was no significant difference in the abdominal blood vessels of the experimental group relative to the control group according to abdominal CT over the 6 months. (2) Our study demonstrates statistically significant effects of FIR therapy on the following parameters: creatinine (p = 0.039 *) and hs-CRP (p < 0.001 **) levels decreased significantly, and eGFR (p = 0.043 *), glucose (p < 0.001 **), and albumin (p = 0.048 *) levels increased significantly. Our study found that in the experimental group, creatinine and hs-CRP levels decreased significantly due to FIR therapy for 6 months. However, our study also found that the glucose level was significantly different

after FIR therapy for 6 months. Peritoneal dialysis combined with FIR can reduce the side effects of the glucose in the dialysis buffer, which interferes with peritoneal inflammation and peritoneal mesothelial cell fibrosis. (3) In addition, we also found that no statistically significant difference in any inflammatory cytokine after FIR therapy. IFN- (p = 0.124), IL-12p70 (p = 0.093), IL-18 (p = 0.213), and TNF- (p = 0.254) did not exhibit significant improvements after peritoneal dialysis with FIR treatment over 6 months. Conclusions: We found that the effectiveness of peritoneal dialysis was improved significantly with FIR therapy, and significant improvements in the peritoneal permeability and inflammatory response were observed.

-J Clin Med. 2022 Mar 15;11(6):1624.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
February 12, 2026
On 9–10 February 2026, FIRAPY joined Unex Corporation (Japan) at World Health Expo – WHX Dubai 2026, held at the Dubai Exhibition Centre, Expo City Dubai. This was FIRAPY’s first time participating in WHX Dubai, marking an important step in expanding our presence in the Middle East and surrounding regions.  WHX Dubai (World Health Expo) is one of the region’s most important healthcare exhibitions, bringing together thousands of healthcare professionals, industry leaders, and innovators from more than 100 countries. The event combines a large-scale trade show with conferences and forums that highlight new technologies, clinical best practices, and emerging models of care.
December 29, 2025
Authors: Hamed Ali Ahmad Alshahri, Omaima Farah Al Jabal Published in: World Advances in Renal Medicine Vol.1, No.3 (2025) Read the full article
42th Chilean Society of Nephrology
December 3, 2025
FIRAPY made its debut at the Chilean Society of Nephrology Congress, presented by Mirusta and featured in a fistula care workshop, sparking local clinical interest.
More Posts